An investigator-sponsored, open-label, single dose, safety and tolerability study clinical study of a Durasert implant to treat severe OA of the knee.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Dexamethasone (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- 11 Sep 2017 Enrollment of this trial has been completed by Hospital for Special Surgery (HSS), as reported in a pSivida media release. 24-week data from this trial expected in 2018.
- 11 Sep 2017 Status changed from recruiting to active, no longer recruiting, as reported in a pSivida media release
- 04 May 2017 According to pSivida media release, the company expects to to report the initial 24-week data by the fourth quarter of 2017.